A human monoclonal 1 antibody blocking SARS-CoV-2 infection
Nisreen M.A. Okba,
Rien van Haperen,
Albert D.M.E. Osterhaus,
Frank J.M. van Kuppeveld,
Bart L. Haagmans,
Posted 12 Mar 2020
bioRxiv DOI: 10.1101/2020.03.11.987958 (published DOI: 10.1038/s41467-020-16256-y)
Posted 12 Mar 2020
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19.
- Downloaded 99,811 times
- Download rankings, all-time:
- Site-wide: 9 out of 85,232
- In microbiology: 2 out of 7,252
- Year to date:
- Site-wide: 5 out of 85,232
- Since beginning of last month:
- Site-wide: 25 out of 85,232
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!